IPAR

Publicly Available Assessment Report for a
Veterinary Medicinal Product

CEEMAST Dry Cow Intramammary Suspension

PRODUCT SUMMARY

Name, strength and pharmaceutical form	Ceemast Dry Cow Intramammary Suspension
Active substance(s)	Cefalexin, dihydrostreptomycin
Applicant	Bimeda Animal Health Limited, 2, 3 & 4 Airton Close Airton Road Tallaght Dublin 24 Ireland
Legal basis of application	Informed consent application in accordance with Article 13c of Directive 2001/82/EC as amended.
Date of Authorisation	15th February 2008
Target species	Dry cows
Indication for use	Treatment of subclinical mastitis infection present at drying off in cows and to assist in preventing new infections occurring during the dry period.
ATCvet code	QJ51RD01

PUBLIC ASSESSMENT REPORT

The public assessment report reflects the scientific conclusion reached by the HPRA at the end of the evaluation process and provides a summary of the grounds for approval of the marketing authorisation for the specific veterinary medicinal product. It is made available by the HPRA for information to the public, after the deletion of commercially confidential information. The legal basis for its creation and availability is contained in Article 25.4 of EC Directive 2001/82/EC as amended by Directive 2004/28/EC for veterinary medicinal products. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the product for marketing in Ireland.

The Summary of Product Characteristics (SPC) for this product is available on the HPRA's website.

I. SCIENTIFIC OVERVIEW

The initial application for the reference product, Kefamast Dry Cow Intramammary Suspension, was assessed before there was a requirement to have a public assessment report, therefore no details in this section are available. Please refer to Section VI for significant post-approval changes which are important for the quality, safety and efficacy of the product.

II. QUALITY ASPECTS

See section I.

III SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

See section I.

IV. CLINICAL ASSESSMENT

See section I.

V. OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

On the basis of the original data submitted for the reference product (Kefamast Dry Cow), the HPRA considered that Ceemast Dry Cow demonstrated adequate evidence of efficacy for the approved indication as well as a satisfactory risk/benefit profile and therefore granted a marketing authorisation.

VI. POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the HPRA website.

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

None.